Alpha-9 Oncology Initiates Phase 1 Trial of Novel Actinium-225 Radiotherapeutic for Melanoma
Key Insights
Alpha-9 Oncology (search) has dosed the first patient in a Phase 1 study of A9-3408 (search), an Actinium-225-based radiotherapeutic targeting melanocortin 1 receptor (search) (MC1R (search)) for melanoma (search) treatment.
The multi-center, open-label trial will evaluate safety, dosimetry, and dose escalation in patients with MC1R (search)-positive melanoma (search) who have progressed on standard-of-care therapies.
Previous imaging studies with A9-3202 showed 92% of patients had strong MC1R (search) expression after immunotherapy progression, demonstrating significant therapeutic potential.
Alpha-9 Oncology (search) has achieved a significant milestone in melanoma (search) treatment by dosing the first patient in a Phase 1 study of A9-3408 (search), a novel Actinium-225-based radiotherapeutic targeting melanocortin 1 receptor (search) (MC1R (search)). The multi-center, open-label trial is designed to evaluate the safety, dosimetry, and dose escalation of A9-3408 in patients with MC1R-positive melanoma who have progressed on standard-of-care therapies.
Targeting an Ideal Receptor
The MC1R (search) target represents a promising approach for melanoma (search) treatment due to its unique expression profile. "MC1R is an ideal target due to its high expression in melanoma and limited presence in healthy tissue," said Robert Meehan, M.D., Chief Medical Officer at Alpha-9. This selective expression pattern offers the potential for targeted therapy with minimal off-target effects.
The therapeutic potential of this approach is supported by compelling clinical data from Alpha-9's companion imaging agent. In the company's A9-3202 imaging study, 92% of patients demonstrated strong MC1R (search) expression after progression on immunotherapy, highlighting the substantial patient population that could benefit from this targeted radiotherapeutic approach.
Addressing Unmet Medical Need
Despite significant advances in immunotherapy for melanoma (search), substantial treatment gaps remain for patients who progress on current standard-of-care therapies. "Despite advances in immunotherapy, significant unmet needs remain for patients who progress on current standard of care," noted Dr. Meehan. The high prevalence of MC1R (search) expression in post-immunotherapy patients suggests that A9-3408 (search) could provide a new treatment modality for this challenging patient population.
Building on Established Platform
The Phase 1 study advances Alpha-9's melanoma (search) program, which first entered the clinic last year with A9-3202, a Gallium-68-based imaging agent used to assess MC1R (search) expression and identify patients suitable for the A9-3408 (search) therapeutic study. This companion diagnostic approach enables precision patient selection for the radiotherapeutic treatment.
"Dosing the first patient with our MC1R (search) radiotherapeutic marks an important milestone for the company and validates our internal R&D platform," said Paul Blanchfield, Chief Executive Officer of Alpha-9 Oncology (search). "We are excited to have initiated trials for our first therapeutic program and look forward to advancing additional best-in-class assets into the clinic as we aim to bring novel, life-improving treatments to people living with cancer."
Leadership Enhancement
Alpha-9 has strengthened its clinical development capabilities with the appointment of Robert Meehan, M.D., as Chief Medical Officer. Dr. Meehan brings extensive experience in biopharma and biotechnology, specializing in complex, novel development programs. He is a board-certified physician trained in hematology and oncology, with expertise across all phases of drug development and multiple therapeutic modalities.
Prior to joining Alpha-9, Dr. Meehan served as Senior Vice President of Clinical Development at Dragonfly Therapeutics (search), held multiple senior clinical leadership roles at Moderna, and worked as a staff clinician in the Developmental Therapeutics Clinic at the National Cancer Institute.
Precision Radiotherapeutic Platform
Alpha-9's platform employs a systematic approach to molecule design, optimizing binders, linkers, and chelators to create radiotherapeutics with superior uptake and retention in tumors while minimizing off-target effects. The advancement of the MC1R (search) program demonstrates the company's capability to develop best-in-class molecules and deliver on the promise of precision oncology.
The clinical-stage radiotherapeutic company applies proprietary technologies, deep foundational expertise, and the ability to work with multiple isotopes to engineer and optimize novel radiotherapeutics that selectively deliver tumor-killing radiation while minimizing effects on healthy tissue.